Cargando…

The Efficacy and Safety of Rapamycin in Children with Tuberous Sclerosis: A Cross-sectional Study

OBJECTIVES: Mutations in TSC1 or TSC2 genes have been proposed as the main causative factors responsible for developing Tuberous Sclerosis Complex (TSC). Given the effect of these two genes on the mTOR pathway, rapamycin has emerged as a novel therapeutic agent. The present study evaluated the effec...

Descripción completa

Detalles Bibliográficos
Autores principales:	TEHRANI, Fateme, KHOSROSHAHI, Nahideh, KEIHANI DOUST, Zarrin, DABIRAN, Soheila, ZARKESH, Mohammad Reza
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Shahid Beheshti University of Medical Sciences 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10114273/ https://www.ncbi.nlm.nih.gov/pubmed/37091468 http://dx.doi.org/10.22037/ijcn.v17i2.36243

Ejemplares similares

Antiepileptic Effect and Safety Profile of Rapamycin in Pediatric Patients With Tuberous Sclerosis Complex
por: Sadowski, Krzysztof, et al.
Publicado: (2022)

Mammalian target of rapamycin inhibitors for treatment in tuberous sclerosis
por: Kim, Won Seop
Publicado: (2011)

Topical rapamycin for facial angiofibromas in tuberous sclerosis complex
por: Safa, Gilles
Publicado: (2017)

Efficacy and safety of mTOR inhibitors (rapamycin and its analogues) for tuberous sclerosis complex: a meta-analysis
por: Li, Min, et al.
Publicado: (2019)

Retraction: Mammalian target of rapamycin inhibitors for treatment in tuberous sclerosis
por: Kim, Won Seop
Publicado: (2013)

Safety of inactivated COVID-19 vaccine in tuberous sclerosis complex patients with epilepsy treated with rapamycin
por: Lu, Qian, et al.
Publicado: (2022)

Rapamycin weekly maintenance dosing and the potential efficacy of combination sorafenib plus rapamycin but not atorvastatin or doxycycline in tuberous sclerosis preclinical models
por: Lee, Nancy, et al.
Publicado: (2009)

Topical Rapamycin Therapy to Alleviate the Cutaneous Manifestations of Tuberous Sclerosis Complex: A Double-Blind, Randomized, Controlled Trial to Evaluate the Safety and Efficacy of Topically Applied Rapamycin
por: Koenig, Mary Kay, et al.
Publicado: (2012)

Cooperative benefit for the combination of rapamycin and imatinib in tuberous sclerosis complex neoplasia
por: Govindarajan, Baskaran, et al.
Publicado: (2012)

Efficacy and safety of a mammalian target of rapamycin inhibitor in pediatric patients with tuberous sclerosis complex: A systematic review and meta-analysis
por: YANG, GUANG, et al.
Publicado: (2015)

Diagnostic Value of the Urine Mucus Test in Childhood Masturbation among Children below 12 Years of Age: A Cross-Sectional Study from Iran
por: Doust, Zarin Keihani, et al.
Publicado: (2016)

Rapamycin reverses impaired social interaction in mouse models of tuberous sclerosis complex
por: Sato, Atsushi, et al.
Publicado: (2012)

Assessing the effectiveness of rapamycin on angiomyolipoma in tuberous sclerosis: a two years trial
por: Cabrera-López, Cristina, et al.
Publicado: (2012)

Topical rapamycin inhibits tuberous sclerosis tumor growth in a nude mouse model
por: Rauktys, Aubrey, et al.
Publicado: (2008)

Tuberous Sclerosis Associated with Polycystic Kidney Disease: Effects of Rapamycin after Renal Transplantation
por: Rosado, C., et al.
Publicado: (2013)

Rapamycin-Insensitive Up-Regulation of Adipocyte Phospholipase A2 in Tuberous Sclerosis and Lymphangioleiomyomatosis
por: Li, Chenggang, et al.
Publicado: (2014)

Efficacy and Safety of Topical Mechanistic Target of Rapamycin Inhibitors for Facial Angiofibromas in Patients with Tuberous Sclerosis Complex: A Systematic Review and Network Meta-Analysis
por: Lin, Yu-Ting, et al.
Publicado: (2022)

MicroRNA-21 is Induced by Rapamycin in a Model of Tuberous Sclerosis (TSC) and Lymphangioleiomyomatosis (LAM)
por: Trindade, Anil J., et al.
Publicado: (2013)

Insulinoma and Tuberous Sclerosis: A Possible Mechanistic Target of Rapamycin (mTOR) Pathway Abnormality?
por: Kang, Michael Yoon, et al.
Publicado: (2017)

Rapamycin therapy for neonatal tuberous sclerosis complex with cardiac rhabdomyomas: A case report and review
por: Mao, Shanshan, et al.
Publicado: (2017)

Inhibition of the mechanistic target of rapamycin induces cell survival via MAPK in tuberous sclerosis complex
por: Lu, Yiyang, et al.
Publicado: (2020)

Efficacy and Safety of Topical Timolol for the Treatment of Facial Angiofibroma in Children with Tuberous Sclerosis Complex
por: Ghazavi, Mohammadreza, et al.
Publicado: (2023)

Tuberous sclerosis preclinical studies: timing of treatment, combination of a rapamycin analog (CCI-779) and interferon-gamma, and comparison of rapamycin to CCI-779
por: Messina, Michael P, et al.
Publicado: (2007)

Combined Targeting of mTOR and Akt Using Rapamycin and MK-2206 in The Treatment of Tuberous Sclerosis Complex
por: Ji, Shuang, et al.
Publicado: (2017)

Radiological Characteristics of Renal Lesions During Tuberous Sclerosis Complex: Impact of Mechanistic Target of Rapamycin Inhibitor Treatment
por: Pfirmann, Pierre, et al.
Publicado: (2022)

Tuberous sclerosis
por: George, Anisha, et al.
Publicado: (2015)

Comparative Evaluation between Diameter Difference of the Thumb and Asymmetry of Lateral Cerebral Ventricles in Children with Developmental Delay: A New Finding
por: KEIHANI DOUST, Zarintaj, et al.
Publicado: (2015)

Health-Related Quality of Life in Iranian Women with Different Levels of Physical Activity
por: Farid, Maliheh, et al.
Publicado: (2012)

The tuberous sclerosis proteins regulate formation of the primary cilium via a rapamycin-insensitive and polycystin 1-independent pathway
por: Hartman, Tiffiney R., et al.
Publicado: (2009)

Long-term efficacy and safety of sirolimus for retinal astrocytic hamartoma associated with tuberous sclerosis complex
por: Zhang, Chen-Xi, et al.
Publicado: (2022)

AUTISM IN TUBEROUS SCLEROSIS
por: Khanna, Rakesh, et al.
Publicado: (1991)

Tuberous sclerosis with rhabdomyoma
por: Ajay, V., et al.
Publicado: (2013)

Tuberous (or Tuberose) Sclerosis
por: Fowler, J. S., et al.
Publicado: (1910)

Translatome analysis of Tuberous Sclerosis Complex-1 patient-derived neural progenitor cells reveal rapamycin-dependent and independent alterations
por: Aksoylu, Inci S., et al.
Publicado: (2023)

Translatome analysis of tuberous sclerosis complex 1 patient-derived neural progenitor cells reveals rapamycin-dependent and independent alterations
por: Aksoylu, Inci S., et al.
Publicado: (2023)

Tubers and Tumors Are CLIPped Together in Tuberous Sclerosis Complex
por: Dang, Louis
Publicado: (2022)

All tubers are not created equal: Cerebellar tubers in a pediatric patient with tuberous sclerosis
por: Weerasinghe, Sanjeeva, et al.
Publicado: (2020)

TuberOus SClerosis registry to increAse disease awareness (TOSCA) Post-Authorisation Safety Study of Everolimus in Patients With Tuberous Sclerosis Complex
por: Kingswood, J. Chris, et al.
Publicado: (2021)

Topical Rapamycin for Facial Angiofibromas in a Child with Tuberous Sclerosis Complex (TSC): A Case Report and Long-Term Follow-up
por: Ebrahimi-Fakhari, Daniel, et al.
Publicado: (2017)

Risk factors for mortality in fulminant acute necrotizing encephalopathy following influenza A in an adolescent boy
por: Khosroshahi, Nahideh, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_34v0f4jpggr2vh0h3g47498c9r